Junshi Biosciences (01877) Receives Full Approval from NMPA for Toripalimab in Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-Containing Chemotherapy Failure
Stock News
Oct 28
Junshi Biosciences (01877) announced that the company recently received a Drug Supplementary Application Approval Notice issued by the National Medical Products Administration (NMPA), approving the indication of toripalimab injection (trade name: TUOYI®, product code: JS001) as a monotherapy for patients with locally advanced or metastatic urothelial carcinoma who have failed platinum-containing chemotherapy, including disease progression within 12 months of neoadjuvant or adjuvant chemotherapy. The approval has been converted from conditional approval to full approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.